Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This opinion article reviews various pathways through which onabotulinumtoxinA might work in medical treatments, highlighting applications beyond muscle paralysis, including pain inhibition and potential effects on hair loss and cancer cell apoptosis.

This study found that the tetracycline-regulated transcription system effectively controls conditional gene expression in the mouse epidermis, allowing suppression and activation of specific genes with doxycycline.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

In this study, researchers using Arabidopsis thaliana found that adenosine may inhibit root hair growth and stomatal opening, suggesting it plays a signaling role in plants similar to its function in animal cells, potentially revealing a new adenosine-like receptor pathway.

This study demonstrated that adenosine triphosphate may prevent vandetanib-induced skin toxicity in rats, suggesting potential for further research in other animal models and humans.

This article reviewed literature and found that Alginate-Chitosan-Fucoidan sponges may offer effective alternatives for wound dressing due to their enhanced wound healing abilities, attributed to good hemostatic and antibacterial properties, as well as excellent elasticity.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study found that introducing rat ornithine transcarbamylase gene into spf-ash mice improved liver and intestinal enzyme activity and normalized some metabolic indicators.

This study found that CTIP2 is highly expressed in mouse skin during embryogenesis and adulthood, suggesting it may play a role in skin development and homeostasis.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

This study concluded that GLCAT14A-C genes are crucial for the function of glucuronic acid transfer to AGPs in Arabidopsis, affecting various growth and reproductive traits such as seed germination and root hair growth.

This review discusses the role of astrotactins in development and their genetic mutations' links to a variety of human diseases, but reports no new clinical results.

This study found that betibeglogene autotemcel significantly improved transfusion independence in 89% of patients with transfusion-dependent beta-thalassemia, although the high cost and manufacturing challenges may limit widespread adoption.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

This article discusses the various titles given to individuals assisting in hair transplant surgeries and provides no clinical research findings.

The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.

In this study, 60% of patients with alopecia totalis showed partial hair regrowth after being treated with triamcinolone acetonide injections, with one patient achieving complete regrowth and responding well to further immunotherapy.

This study concluded that the best approach for detecting Androsta-1,4,6-triene-3,17-dione administration in horses is monitoring the metabolites M1b or M4 in urine, detectable up to 77 hours post-administration.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This study is collecting real-world data to evaluate abrocitinib and conventional systemic treatments in moderate-to-severe atopic dermatitis across five European registers over a three-year period.

In this report, two adult patients with Tatton-Brown-Rahman syndrome exhibited new cardiac features, such as atrial fibrillation and ventricular and atrial dilatation, highlighting the importance of cardiovascular follow-up in adults with this condition.

This review discusses the development and clinical progression of PROTAC technology for targeted protein degradation, highlighting its potential to address previously "undruggable" targets but reports no new clinical results.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

Targeting TCR-Vβ2 in cutaneous T cell lymphoma shows promise for safer, more specific treatment.